Current Approaches to Novel Therapeutics in Pancreatic Cancer

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2003 Jun 11

PMID 12795537

Citations 3

Authors

Corina E Akerele

Irina Rybalova

Howard L Kaufman

Sridhar Mani

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is one of the most refractory neoplasms to medical treatment. Until now there has been only modest improvement in the treatment of this disease. Standards of care for combined-modality treatment of resectable as well as locally advanced, unresectable disease have not been uniformly accepted to date because of an equivocal or conflicting data. The inception of gemcitabine introduced the new era in the management of metastatic pancreatic cancer, however, new therapeutic approaches still need to be defined. The article discusses the current knowledge of the biology of this lethal disease, its impact on treatment options, and explores novel therapeutic modalities that are likely to improve outcomes and survival for patients in the future.

Citing Articles

Inactivation of Lactobacillus leichmannii ribonucleotide reductase by 2',2'-difluoro-2'-deoxycytidine 5'-triphosphate: covalent modification.

Lohman G, Stubbe J Biochemistry. 2010; 49(7):1404-17.

PMID: 20088569 PMC: 2855214. DOI: 10.1021/bi902132u.

Loss of the eukaryotic initiation factor 3f in pancreatic cancer.

Doldan A, Chandramouli A, Shanas R, Bhattacharyya A, Cunningham J, Nelson M Mol Carcinog. 2007; 47(3):235-44.

PMID: 17918192 PMC: 2568992. DOI: 10.1002/mc.20379.

Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer.

Ohashi M, Yoshida K, Kushida M, Miura Y, Ohnami S, Ikarashi Y Br J Cancer. 2005; 93(4):441-9.

PMID: 16106250 PMC: 2361577. DOI: 10.1038/sj.bjc.6602713.

References

Rich T, Evans D . Preoperative combined modality therapy for pancreatic cancer. World J Surg. 1995; 19(2):264-9. DOI: 10.1007/BF00308636. View

Jeekel J . Treatment perspectives in locally advanced unresectable pancreatic cancer. Br J Surg. 1991; 78(11):1332-4. DOI: 10.1002/bjs.1800781121. View

Greten T, Jaffee E . Cancer vaccines. J Clin Oncol. 1999; 17(3):1047-60. DOI: 10.1200/JCO.1999.17.3.1047. View

Hruban R, Wilentz R, Kern S . Genetic progression in the pancreatic ducts. Am J Pathol. 2000; 156(6):1821-5. PMC: 1850064. DOI: 10.1016/S0002-9440(10)65054-7. View

Warshaw A, Fernandez-Del Castillo C . Pancreatic carcinoma. N Engl J Med. 1992; 326(7):455-65. DOI: 10.1056/NEJM199202133260706. View

Mangray S, King T . Molecular pathobiology of pancreatic adenocarcinoma. Front Biosci. 1998; 3:D1148-60. DOI: 10.2741/a351. View

Via L, Gore-Langton R, Pluda J . Clinical trials referral resource. Current clinical trials administering the antiangiogenesis agent SU5416. Oncology (Williston Park). 2000; 14(9):1312, 1315-6, 1321-3. View

Crowell P, Chang R, Ren Z, Elson C, Gould M . Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem. 1991; 266(26):17679-85. View

Gates Jr L, Ulrich 2nd C, Whitcomb D . Hereditary pancreatitis. Gene defects and their implications. Surg Clin North Am. 1999; 79(4):711-22, vii-viii. DOI: 10.1016/s0039-6109(05)70037-2. View

10.

Hoffman J, Weese J, Solin L, Agarwal P, Engstrom P, Scher R . A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma. Am Surg. 1993; 59(11):772-80; discussion 780-1. View

11.

Moskaluk C, Hruban R, Kern S . p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 1997; 57(11):2140-3. View

12.

Neoptolemos J, Dunn J, Stocken D, Almond J, Link K, Beger H . Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001; 358(9293):1576-85. DOI: 10.1016/s0140-6736(01)06651-x. View

13.

Yamanaka Y, Friess H, Kobrin M, Buchler M, Beger H, Korc M . Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993; 13(3):565-9. View

14.

Apple S, Hecht J, Novak J, Nieberg R, Rosenthal D, Grody W . Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears. Am J Clin Pathol. 1996; 105(3):321-6. DOI: 10.1093/ajcp/105.3.321. View

15.

Smith J, Verderame M, Zagon I . Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer. Cancer Lett. 1999; 135(1):107-12. DOI: 10.1016/s0304-3835(98)00279-1. View

16.

Swift M, Sholman L, Perry M, Chase C . Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res. 1976; 36(1):209-15. View

17.

Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S . Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol. 2001; 19(4):1118-27. DOI: 10.1200/JCO.2001.19.4.1118. View

18.

Ahlgren J . Epidemiology and risk factors in pancreatic cancer. Semin Oncol. 1996; 23(2):241-50. View

19.

Ghimenti C, Tannergard P, Wahlberg S, Liu T, Giulianotti P, Mosca F . Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumours. Br J Cancer. 1999; 80(1-2):11-6. PMC: 2363009. DOI: 10.1038/sj.bjc.6690314. View

20.

Bouvet M, Bold R, Lee J, Evans D, Abbruzzese J, Chiao P . Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. Ann Surg Oncol. 1998; 5(8):681-8. DOI: 10.1007/BF02303477. View